Excellent
Partially Aligned
Patient Risk:
Info
Summary
All provided statements correspond to general label-consistent aspects and do not conflict with the supplied prescribing information excerpts. However, key claims about pediatric trials are not supported or verifiable from the provided label excerpt content.
Category Scores
Accurate Statements
Polivy clinical trials have evaluated the safety and efficacy of Polivy in adults with NHL.
Supported at a high level: the provided label excerpts include clinical trial safety/efficacy experience for adult populations (e.g., POLARIX and GO29365 peripheral neuropathy incidence). Specific “safety and efficacy” wording for adults is not directly quoted, but the presence of clinical trial experience in adults supports the general claim.
There is a lack of clinical trials evaluating the safety and efficacy of Polivy in children.
Not supported by the provided excerpt content; cannot be confirmed from the supplied label sections shown.
Unsupported Statements
Polivy (polatuzumab vedotin) is a monoclonal antibody-drug conjugate (ADC) used in the treatment of certain types of non-Hodgkin lymphoma (NHL).
The provided excerpts focus on peripheral neuropathy management (sections 2.2, 5.1, 6.1, 17) and do not include the label’s mechanism description (ADC) or the approved indications section content needed to verify this claim.
There is a lack of clinical trials evaluating the safety and efficacy of Polivy in children.
The provided excerpts contain no pediatric-specific trial statements; therefore this claim cannot be verified from the supplied label content.
There are no pediatric clinical trials currently listed on ClinicalTrials.gov for Polivy.
The supplied prescribing information excerpts do not address ClinicalTrials.gov listings; therefore this claim is unsupported by the label content provided.
Contradictions
Important Omissions
For pediatric-trial-related claims: the label sections on Use in Specific Populations (e.g., pediatrics) are not included in the supplied excerpt, so material information needed to assess whether pediatric trials exist/is absent is missing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Info
The only clearly label-addressed content in the excerpt concerns peripheral neuropathy. The pediatric/ClinicalTrials.gov claims are unsupported by the provided label text, which could mislead decision-making if taken as factual.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Pediatric trial and ClinicalTrials.gov claims are not supported by the supplied prescribing information excerpts.
Suggested Improvement
Remove or rephrase pediatric-related statements unless pediatric-use/trial information is included in the provided label sections (e.g., Use in Specific Populations). Limit mechanism/indication claims to label excerpts that explicitly state ADC nature and approved indications.